Funding Opportunity PA-20-265 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

Notice NOT-AI-20-062 from the NIH Guide for Grants and Contracts

Notice NOT-ES-20-021 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-20-262 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Funding Opportunity PA-20-261 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH0 invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Funding Opportunity PA-20-260 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

Notice NOT-OD-20-143 from the NIH Guide for Grants and Contracts

Notice NOT-DK-20-035 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-21-026 from the NIH Guide for Grants and Contracts. Recent technical advancements have enabled generating human cell-mice chimeric brains by engrafting human iPSC-derived primitive neural progenitor cells and/or cord blood-derived microglial progenitor cells into neonatal mouse. In the chimeric brain, human neural progenitor cells or microglial cells differentiate, migrate, and distribute throughout the mouse brain. They are eventually functionally integrated into various brain regions. Such successes provide opportunities to define the structure, function, genetics and plasticity of functional neural networks containing human cells. It can also serve as a rodent model to study HIV infectivity, provirus activity, reservoir formation, and the neuropathogenesis of HIV infection. It allows the study of HIV and substance abuse comorbidity in the brain of a fully functional, awake, behaving animal from the single cell to neural circuitry levels.

Notice NOT-AA-20-017 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-256 from the NIH Guide for Grants and Contracts. The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAIDs vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAIDs emergency appropriation provided by The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 and The Coronavirus Aid, Relief and Economic Security (CARES) Act.

Funding Opportunity PAR-20-129 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award. Clinical Trials are not accepted under this FOA.

Funding Opportunity PAR-20-128 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a Food and Drug Administration (FDA) submission, development of an intellectual property strategy, and/or planning for a clinical trial. Although a significant amount of the work in a CRP award may be subcontracted to other organizations, the SBC is expected to maintain oversight and management of the R and D throughout the award. Clinical trials not accepted under this FOA.

Funding Opportunity PAR-20-130 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award. This Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Funding Opportunity RFA-DK-20-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.

Notice NOT-NS-20-088 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-087 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-086 from the NIH Guide for Grants and Contracts

Notice NOT-GM-20-044 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-076 from the NIH Guide for Grants and Contracts